US FDA rejects sutimlimab for cold agglutinin disease (CAD)
The FDA rejection was due to deficiencies from a pre-license inspection of a third-party manufacturing facility. Sutimlimab, a monoclonal antibody targeting C1s (serine protease within the C1-complex) was expected to be the first treatment approved for the treatment of CAD.
Source:
Biospace Inc.